| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-04-1028 |
| P698 | PubMed publication ID | 15585616 |
| P2093 | author name string | Peter D Senter | |
| Che-Leung Law | |||
| Kerry Klussman | |||
| Dana F Chace | |||
| Joseph A Francisco | |||
| Alan F Wahl | |||
| Charles G Cerveny | |||
| Clay B Siegall | |||
| Damon L Meyer | |||
| Svetlana O Doronina | |||
| Kristine A Gordon | |||
| Bruce J Mixan | |||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7842-7851 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates | |
| P478 | volume | 10 |
| Q47095655 | A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates. |
| Q58801878 | Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E |
| Q38818652 | Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study. |
| Q27022321 | Antibody Drug Conjugates: Preclinical Considerations |
| Q38489049 | Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability |
| Q38087390 | Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia |
| Q34449555 | Arming antibodies: prospects and challenges for immunoconjugates |
| Q37342767 | CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies |
| Q39922525 | CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers |
| Q38807514 | CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies |
| Q37854644 | Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates |
| Q101121069 | Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer |
| Q60948062 | EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway |
| Q37329160 | EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma |
| Q49883378 | Fate of Antibody-Drug Conjugates in Cancer Cells |
| Q38144106 | Impact of donor-specific antibodies in reconstructive transplantation |
| Q38537257 | Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates |
| Q41282870 | Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates |
| Q37818256 | Investigational antibody-drug conjugates for hematological malignancies |
| Q36616311 | Issues related to targeted delivery of proteins and peptides |
| Q40315198 | Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates |
| Q37628646 | Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. |
| Q27301080 | Multiscale Framework for Imaging Radiolabeled Therapeutics |
| Q38024991 | Optimising the delivery of tubulin targeting agents through antibody conjugation |
| Q36452621 | Potent antibody therapeutics by design |
| Q37138420 | Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy |
| Q39117341 | Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. |
| Q36982570 | Prodrug strategies in anticancer chemotherapy |
| Q36200735 | Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas |
| Q36773469 | Technology insight: cytotoxic drug immunoconjugates for cancer therapy |
| Q48558433 | The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment |
| Q33311571 | Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy |
Search more.